Fig. 1From: HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world studyThe progression-free survival (PFS) and overall survival (OS) of the two groups. Kaplan–Meier curves of PFS (a) and OS (b) for patients in the LEN-PD1 and HAIC-LEN-PD1 groupsBack to article page